Efficacy of tyrosine kinase inhibitors in non-small-cell lung cancer patients undergoing dose reduction and those with a low body surface area-Reference-Cited by-同舟云学术

Efficacy of tyrosine kinase inhibitors in non-small-cell lung cancer patients undergoing dose reduction and those with a low body surface area

Published:2014-04-16 Issue:4 Volume:2 Page:604-608
ISSN:2049-9450
Container-title:Molecular and Clinical Oncology
language:en
Short-container-title:

Author:

SATO SHINYA,KURISHIMA KOICHI,MIYAZAKI KUNIHIKO,KODAMA TAKAHIDE,ISHIKAWA HIROICHI,KAGOHASHI KATSUNORI,TAMURA TOMOHIRO,HOMMA SHINSUKE,SATOH HIROAKI,HIZAWA NOBUYUKI

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of body surface area on efficacy and safety in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib as a first-line treatment;Cancer Treatment and Research Communications;2024

2. Management of diarrhea induced by EGFR-TKIs in advanced lung adenocarcinoma;Therapeutic Advances in Medical Oncology;2023-01

3. Treatment Effectiveness and Tolerability of Long-term Adjuvant First- and Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor at Different Doses in Patients With Stage IIA–IIIB Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Retrospective Study;Frontiers in Surgery;2022-03-11

4. Efficacy of gefitinib at reduced dose in EGFR mutant non-small cell lung carcinoma;Anti-Cancer Drugs;2019-11

5. Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis;BMC Cancer;2018-08-02